Feasibility, Usability, and Acceptability of Virtual Reality-Based Cognitive and Physical Rehabilitation in Individuals With Mild Cognitive Impairment ((VR-MCI))
Feasibility, Usability, and Acceptability of Virtual Reality-Based Cognitive and Physical Rehabilitation in Individuals With Mild Cognitive Impairment (VR-MCI)
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Seema S Aggarwal, PhD, APRN, AGNP-C
- Telefonnummer: (713) 500-9946
- E-mail: Seema.S.Aggarwal@uth.tmc.edu
Undersøgelse Kontakt Backup
- Navn: Tela Todd
- Telefonnummer: (713) 500-7039
- E-mail: Tela.Todd@uth.tmc.edu
Studiesteder
-
-
Texas
-
Houston, Texas, Forenede Stater, 77030
- Rekruttering
- The University of Texas Health Science Center at Houston
-
Kontakt:
- Tela Todd
- Telefonnummer: (713) 500-7039
- E-mail: Tela.Todd@uth.tmc.edu
-
Kontakt:
- Seema Aggarwal, PhD, APRN, AGNP-C
- Telefonnummer: (713) 500-9946
- E-mail: Seema.S.Aggarwal@uth.tmc.edu
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Beskrivelse
Inclusion Criteria:
- Clinical diagnosis of MCI (MoCA 18-26) or self-reported subjective cognitive decline (SCD)
- Capacity to provide informed consent
- Able to provide own transportation to sessions
- Speaks and understands English
- Ambulatory
Exclusion Criteria:
- Uncontrolled seizures or epilepsy
- Severe psychiatric illness or active suicidality
- Inability to follow instructions or tolerate VR (severe motion sickness)
- Cognitive impairment as a result of a known cause (e.g., dementia, stroke, Traumatic Brain Injury (TBI), medications, etc.)
- Any condition that the research team determines would interfere with safe participation
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Enhedens gennemførlighed
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Virtual Reality (VR) sessions
|
Participants will complete 3 supervised virtual reality (VR) sessions per week for 6 weeks for a total of 18 sessions using either the Real System VR headset or the Oculus Quest 2 VR headset.
Each session will last approximately 60 minutes, with time allocated for setup and brief symptom checks.
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Feasibility as assessed by the recruitment rate
Tidsramme: from baseline to end of intervention (6 weeks)
|
from baseline to end of intervention (6 weeks)
|
|
|
Feasibility as assessed by the retention rate
Tidsramme: from baseline to end of intervention (6 weeks)
|
from baseline to end of intervention (6 weeks)
|
|
|
Feasibility as assessed by the session completion rate
Tidsramme: from baseline to end of intervention (6 weeks)
|
from baseline to end of intervention (6 weeks)
|
|
|
Usability as assessed by the System Usability Scale (SUS)
Tidsramme: Post-intervention only (Final visit at 6 weeks)
|
The System Usability Scale (SUS) is a validated 10-item questionnaire used to assess participants' perceived usability of the intervention.
each rated on a 5-point Likert scale from 1 = Strongly Disagree, 2 = Disagree 3 = Neutral ,4 = Agree, 5 = Strongly Agree.
Scores range from 0 to 100, with higher scores indicating greater usability.
|
Post-intervention only (Final visit at 6 weeks)
|
|
Acceptability / Presence as assessed by the Presence Questionnaire (PQ)
Tidsramme: Post-intervention only (Final visit at 6 weeks)
|
This is a 29 item questionnaire, each is scored on a seven-point Likert-type scale with a score range form 29-203. Higher scores indicate a greater sense of presence or immersion in the virtual environment.
|
Post-intervention only (Final visit at 6 weeks)
|
|
Tolerability / Side Effects as assessed by the Simulator Sickness Questionnaire (SSQ)
Tidsramme: Before + immediately After each VR session
|
This is a 16 item questionnaire and each is scored form 0(none) to 3(severe).
Scores are combined using weighted subscales to generate a total score, with higher scores indicating greater simulator sickness
|
Before + immediately After each VR session
|
|
Adherence / Engagement as assessed by the session attendance as entered in VR system logs
Tidsramme: Post-intervention only (Final visit at 6 weeks)
|
Post-intervention only (Final visit at 6 weeks)
|
|
|
Adherence / Engagement as assessed by the time from start to end of VR session as entered in VR system logs
Tidsramme: Post-intervention only (Final visit at 6 weeks)
|
Post-intervention only (Final visit at 6 weeks)
|
|
|
Adherence / Engagement as assessed by the number of repetitions of the activity as indicated by device metrics
Tidsramme: Post-intervention only (Final visit at 6 weeks)
|
Post-intervention only (Final visit at 6 weeks)
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Samarbejdspartnere
Samarbejdspartnere
Efterforskere
Efterforskere
- Ledende efterforsker: Seema Aggarwal, PhD, APRN, AGNP-C, The University of Texas Health Science Center, Houston
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- HSC-MS-26-0038
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .